Translational Development Acquisition Corp. Files S-1
Ticker: TDACW · Form: S-1 · Filed: Oct 22, 2024 · CIK: 1926599
Sentiment: neutral
Topics: spac, s-1, ipo
TL;DR
SPAC filing from Translational Development Acquisition Corp. is in!
AI Summary
Translational Development Acquisition Corp. filed an S-1 registration statement on October 22, 2024, for a proposed public offering. The company, incorporated in the Cayman Islands, is a blank check company with its principal executive offices located at 52 E 83rd St., New York, NY. Michael B. Hoffman serves as the Chief Executive Officer.
Why It Matters
This S-1 filing indicates that Translational Development Acquisition Corp. is preparing to go public, which could lead to a future acquisition or merger opportunity in the blank check company space.
Risk Assessment
Risk Level: medium — As a blank check company (SPAC), its success is contingent on finding and completing a business combination, which carries inherent risks.
Key Numbers
- 333-282763 — SEC File Number (Identifies this specific registration filing with the SEC.)
- 6770 — SIC Code (Indicates the company operates in the 'BLANK CHECKS' industry.)
Key Players & Entities
- Translational Development Acquisition Corp. (company) — Registrant
- Michael B. Hoffman (person) — Chief Executive Officer
- Cayman Islands (location) — Jurisdiction of incorporation
- 52 E 83RD ST., NEW YORK, NY 10028 (address) — Principal executive offices
- October 22, 2024 (date) — Filing date
FAQ
What is the primary purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for Translational Development Acquisition Corp. to register its securities for a public offering.
When was this S-1 filing submitted?
The S-1 filing was submitted on October 22, 2024.
Where is Translational Development Acquisition Corp. incorporated?
Translational Development Acquisition Corp. is incorporated in the Cayman Islands.
Who is the Chief Executive Officer of Translational Development Acquisition Corp.?
Michael B. Hoffman is the Chief Executive Officer of Translational Development Acquisition Corp.
What is the business address of the company?
The business address is 52 E 83RD ST., NEW YORK, NY 10028.
Filing Stats: 4,633 words · 19 min read · ~15 pages · Grade level 16.6 · Accepted 2024-10-22 08:53:09
Key Financial Figures
- $150,000,000 — ational Development Acquisition Corp. $150,000,000 15,000,000 Units Translational Deve
- $10.00 — ies. Each unit has an offering price of $10.00 and consists of one Class A ordinary sh
- $11.50 — ne Class A ordinary share at a price of $11.50 per share, subject to adjustment as des
- $1.00 — e, subject to adjustment, at a price of $1.00 per warrant, or $5,650,000 (or $6,212,5
- $5,650,000 — nt, at a price of $1.00 per warrant, or $5,650,000 (or $6,212,500 if the underwriters' ove
- $6,212,500 — of $1.00 per warrant, or $5,650,000 (or $6,212,500 if the underwriters' over-allotment opt
- $25,000 — d an TABLE OF CONTENTS aggregate of $25,000, or approximately $0.006 per founder sh
- $0.006 — aggregate of $25,000, or approximately $0.006 per founder share, and, accordingly, yo
- $100,000 — interest (less taxes payable and up to $100,000 of interest to pay dissolution expenses
- $0.20 — 9.45 $ 141,750,000 1) Includes $0.20 per unit (including any units sold purs
- $3,000,000 — ption to purchase additional units), or $3,000,000 in the aggregate (or up to $3,450,000 i
- $3,450,000 — r $3,000,000 in the aggregate (or up to $3,450,000 if the underwriters' over-allotment opt
- $0.35 — closing of this offering. Also includes $0.35 per unit on all units sold including th
- $5,250,000 — option to purchase additional units, or $5,250,000 in the aggregate (or up to $6,037,500 i
- $6,037,500 — r $5,250,000 in the aggregate (or up to $6,037,500 in the aggregate if the underwriters' o
Filing Documents
- tm2422367-3_s1.htm (S-1) — 2577KB
- tm2422367d5_ex3-1.htm (EX-3.1) — 117KB
- tm2422367d5_10-1.htm (EX-10.1) — 25KB
- tm2422367d5_ex10-2.htm (EX-10.2) — 21KB
- tm2422367d5_ex10-3.htm (EX-10.3) — 21KB
- tm2422367d5_ex10-7.htm (EX-10.7) — 22KB
- tm2422367d5_ex10-13.htm (EX-10.13) — 11KB
- tm2422367d5_ex10-14.htm (EX-10.14) — 36KB
- tm2422367d5_ex10-15.htm (EX-10.15) — 54KB
- tm2422367d5_ex23-1.htm (EX-23.1) — 4KB
- tm2422367d5_ex99-4.htm (EX-99.4) — 3KB
- tm2422367d5_ex99-5.htm (EX-99.5) — 3KB
- tm2422367d5_ex99-6.htm (EX-99.6) — 3KB
- tm2422367d5_ex99-7.htm (EX-99.7) — 3KB
- tm2422367d5_ex-filingfees.htm (EX-FILING FEES) — 35KB
- tm2422367d5_ex23-1img01.jpg (GRAPHIC) — 6KB
- tm2422367d5_ex23-1img02.jpg (GRAPHIC) — 11KB
- tm2422367d5_ex3-1img001.jpg (GRAPHIC) — 34KB
- tm2422367d5_ex3-1img002.jpg (GRAPHIC) — 117KB
- tm2422367d5_ex3-1img003.jpg (GRAPHIC) — 61KB
- tm2422367d5_ex3-1img004.jpg (GRAPHIC) — 144KB
- tm2422367d5_ex3-1img005.jpg (GRAPHIC) — 149KB
- tm2422367d5_ex3-1img006.jpg (GRAPHIC) — 166KB
- tm2422367d5_ex3-1img007.jpg (GRAPHIC) — 191KB
- tm2422367d5_ex3-1img008.jpg (GRAPHIC) — 232KB
- tm2422367d5_ex3-1img009.jpg (GRAPHIC) — 174KB
- tm2422367d5_ex3-1img010.jpg (GRAPHIC) — 209KB
- tm2422367d5_ex3-1img011.jpg (GRAPHIC) — 225KB
- tm2422367d5_ex3-1img012.jpg (GRAPHIC) — 226KB
- tm2422367d5_ex3-1img013.jpg (GRAPHIC) — 251KB
- tm2422367d5_ex3-1img014.jpg (GRAPHIC) — 243KB
- tm2422367d5_ex3-1img015.jpg (GRAPHIC) — 194KB
- tm2422367d5_ex3-1img016.jpg (GRAPHIC) — 181KB
- tm2422367d5_ex3-1img017.jpg (GRAPHIC) — 212KB
- tm2422367d5_ex3-1img018.jpg (GRAPHIC) — 249KB
- tm2422367d5_ex3-1img019.jpg (GRAPHIC) — 213KB
- tm2422367d5_ex3-1img020.jpg (GRAPHIC) — 240KB
- tm2422367d5_ex3-1img021.jpg (GRAPHIC) — 210KB
- tm2422367d5_ex3-1img022.jpg (GRAPHIC) — 197KB
- tm2422367d5_ex3-1img023.jpg (GRAPHIC) — 248KB
- tm2422367d5_ex3-1img024.jpg (GRAPHIC) — 234KB
- tm2422367d5_ex3-1img025.jpg (GRAPHIC) — 248KB
- tm2422367d5_ex3-1img026.jpg (GRAPHIC) — 203KB
- tm2422367d5_ex3-1img027.jpg (GRAPHIC) — 223KB
- tm2422367d5_ex3-1img028.jpg (GRAPHIC) — 260KB
- tm2422367d5_ex3-1img029.jpg (GRAPHIC) — 203KB
- tm2422367d5_ex3-1img030.jpg (GRAPHIC) — 233KB
- tm2422367d5_ex3-1img031.jpg (GRAPHIC) — 260KB
- tm2422367d5_ex3-1img032.jpg (GRAPHIC) — 116KB
- tm2422367d5_ex3-1img033.jpg (GRAPHIC) — 44KB
- 0001104659-24-110298.txt ( ) — 11727KB
Use of Proceeds
Use of Proceeds 99 Dividend Policy 103
Dilution
Dilution 104 Capitalization 108
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 110 Proposed Business 117 Effecting our Initial Business Combination 128 Management 151 Principal Shareholders 161 Certain Relationships and Related Party Transactions 166
Description of Securities
Description of Securities 169 Taxation 191
Underwriting
Underwriting 203 Legal Matters 214 Experts 214 Where You Can Find Additional Information 214 Index to Financial Statements F-1 We are responsible for the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information that is different from or inconsistent with that contained in this prospectus. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus. i TABLE OF CONTENTS Trademarks This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the or symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. TABLE OF CONTENTS SUMMARY This summary only highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all of the information that you should consider in making an investment decision. You should read this entire prospectus carefully, including the information under "Risk Factors" and our financial statements and the related notes included elsewhere in this prospectus, before investing. Unless otherwise stated in this prospectus or the context otherwise requires, references to: "Companies Act" or "Companies Law" are to the Companies Act (Revised) of the Cayman Islands as the same may be amended fro